Amryt On Targeting Rare Disease Space In The Middle East
The rare and orphan drug company Amryt speaks to the Pink Sheet about how to do business in the Middle East and why seeking marketing authorization could be a better long-term strategy than catering for named patient requests.
You may also be interested in...
The UAE, Jordan, Egypt and Saudi Arabia have all recently announced or implemented new verification/abridged regulatory pathways to improve access to medicines and free up resources.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.